Familial Hypercholesterolemia (Type II Hyperlipoproteinemia):治療薬のグローバル治験動向(2014年上半期)

◆英語タイトル:Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014
◆商品コード:GDHC2138CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年5月15日
◆ページ数:166
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥840,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

Summary

GlobalData’s clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014″ provides data on the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 26
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 34
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen’s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 34
Mar 27, 2014: Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study 36
Mar 17, 2014: Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial Hypercholesterolemia 37
Jan 28, 2014: Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol 38
Jan 23, 2014: Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol 39
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
Sanofi 41
Clinical Trial Overview of Sanofi 41
Aegerion Pharmaceuticals, Inc. 43
Clinical Trial Overview of Aegerion Pharmaceuticals, Inc. 43
Merck & Co., Inc. 45
Clinical Trial Overview of Merck & Co., Inc. 45
Pfizer Inc. 47
Clinical Trial Overview of Pfizer Inc. 47
Regeneron Pharmaceuticals, Inc. 48
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 48
AstraZeneca PLC 49
Clinical Trial Overview of AstraZeneca PLC 49
Novartis AG 50
Clinical Trial Overview of Novartis AG 50
Amgen Inc. 51
Clinical Trial Overview of Amgen Inc. 51
Kowa Company, Ltd. 52
Clinical Trial Overview of Kowa Company, Ltd. 52
Daiichi Sankyo Company, Limited 53
Clinical Trial Overview of Daiichi Sankyo Company, Limited 53
Clinical Trial Overview of Top Institutes / Government 54
National Heart, Lung, and Blood Institute 54
Clinical Trial Overview of National Heart, Lung, and Blood Institute 54
University of Pennsylvania 55
Clinical Trial Overview of University of Pennsylvania 55
Central South University 56
Clinical Trial Overview of Central South University 56
Medical University of Vienna 57
Clinical Trial Overview of Medical University of Vienna 57
Emory University 58
Clinical Trial Overview of Emory University 58
Chinese University of Hong Kong 59
Clinical Trial Overview of Chinese University of Hong Kong 59
University of Sao Paulo 60
Clinical Trial Overview of University of Sao Paulo 60
VU University Medical Center 61
Clinical Trial Overview of VU University Medical Center 61
The Hospital for Sick Children 62
Clinical Trial Overview of The Hospital for Sick Children 62
National Center for Research Resources 63
Clinical Trial Overview of National Center for Research Resources 63
Five Key Clinical Profiles 64
Appendix 164
Abbreviations 164
Definitions 164
Research Methodology 165
Secondary Research 165
About GlobalData 166
Contact Us 166
Disclaimer 166
Source 166

List of Tables
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Aegerion Pharmaceuticals, Inc., 2014* 43
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 45
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 47
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2014* 48
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 49
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 50
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 51
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kowa Company, Ltd., 2014* 52
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 53
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 54
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 55
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Central South University, 2014* 56
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014* 57
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 58
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2014* 59
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 60
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by VU University Medical Center, 2014* 61
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Hospital for Sick Children, 2014* 62
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 63

List of Figures
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 165

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Familial Hypercholesterolemia (Type II Hyperlipoproteinemia):治療薬のグローバル治験動向(2014年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆